AU5871000A - High dose radionuclide complexes for bone marrow suppression - Google Patents

High dose radionuclide complexes for bone marrow suppression

Info

Publication number
AU5871000A
AU5871000A AU58710/00A AU5871000A AU5871000A AU 5871000 A AU5871000 A AU 5871000A AU 58710/00 A AU58710/00 A AU 58710/00A AU 5871000 A AU5871000 A AU 5871000A AU 5871000 A AU5871000 A AU 5871000A
Authority
AU
Australia
Prior art keywords
bone marrow
high dose
marrow suppression
radionuclide complexes
dose radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58710/00A
Other languages
English (en)
Inventor
Paul G. Abrams
James Kyle Bryan
Alan R. Fritzberg
Mark D. Hylarides
Elizabeth K. John
Lauren M. Tatalick
Kent R. Thoelke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of AU5871000A publication Critical patent/AU5871000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU58710/00A 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression Abandoned AU5871000A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US60139065 1999-06-11
US13906599P 1999-07-11 1999-07-11
US14378099P 1999-07-13 1999-07-13
US60143780 1999-07-13
US14982199P 1999-08-19 1999-08-19
US60149821 1999-08-19
PCT/US2000/016052 WO2000076556A2 (en) 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression

Publications (1)

Publication Number Publication Date
AU5871000A true AU5871000A (en) 2001-01-02

Family

ID=27385279

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58710/00A Abandoned AU5871000A (en) 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression

Country Status (6)

Country Link
US (6) US6767531B2 (enExample)
EP (1) EP1191948A2 (enExample)
JP (1) JP2003501488A (enExample)
AU (1) AU5871000A (enExample)
CA (1) CA2371728C (enExample)
WO (1) WO2000076556A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371728C (en) * 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
WO2001091806A2 (en) * 2000-05-31 2001-12-06 Steven Mccullough Measurement of the therapeutic dose for bone marrow ablation therapy
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
WO2002062398A2 (en) * 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
WO2003051403A1 (en) 2001-12-13 2003-06-26 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
CA2509328A1 (en) * 2002-12-10 2004-06-24 University Of Miami Radioablation of hemolymphopoietic cell populations
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
US20070092440A1 (en) * 2003-05-09 2007-04-26 Edgar Braendle Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
US20090252675A1 (en) * 2006-03-29 2009-10-08 Frank R Keith Radionuclide Therapy for Urinary Bladder Cancer
US8625731B2 (en) * 2006-04-14 2014-01-07 Charles S. Holden Compact neutron generator for medical and commercial isotope production, fission product purification and controlled gamma reactions for direct electric power generation
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
TW200809194A (en) * 2006-05-04 2008-02-16 Wyeth Corp Determination of antibiotic concentration in bone
EP2056804B1 (en) * 2006-08-16 2013-05-22 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
US20100310465A1 (en) * 2008-01-23 2010-12-09 The Regents Of The University Of California Nano-devices having releasable seals for controlled release of molecules
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
WO2010078569A2 (en) * 2009-01-05 2010-07-08 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures
EP2399607B1 (en) * 2009-02-18 2017-11-29 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation
US20120207795A1 (en) * 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
WO2012012682A2 (en) 2010-07-22 2012-01-26 Zishan Haroon Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
CN103687590A (zh) 2011-04-28 2014-03-26 Stc·Unm公司 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines
SI3054996T1 (sl) * 2013-10-07 2023-11-30 Igl Pharma, Inc. Postopek za pripravo terapevtskih sredstev za kosti visoke čistote
RU2599874C2 (ru) * 2014-10-13 2016-10-20 Михаил Сергеевич АНОСОВ Способ лечения хронического одонтогенного остеомиелита у наркозависимых больных
US11369700B2 (en) 2015-05-25 2022-06-28 IGL Pharma Inc. DOTMP kit formulations for radioisotopes
JP6930922B2 (ja) * 2015-05-25 2021-09-01 アイジーエル ファーマ，インコーポレイティド 放射性同位体用ｄｏｔｍｐキット製剤
HUE069668T2 (hu) * 2015-12-07 2025-04-28 General Oncology Inc Kombináció a metasztatikus rák hatékony kezelésére betegeknél
WO2017120504A1 (en) 2016-01-08 2017-07-13 Durfee Paul N Osteotropic nanoparticles for prevention or treatment of bone metastases
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
KR20200004861A (ko) 2017-05-05 2020-01-14 퓨전 파마슈티칼즈 인크. Igf-1r 모노클로날 항체 및 그의 용도
CN117603148A (zh) 2017-05-05 2024-02-27 探针技术开发及商业化中心 双官能螯合物的药代动力学增强及其用途
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
JOP20200134A1 (ar) 2017-12-07 2022-10-30 Reven Llc تركيبات وطرق لمعالجة حالات أيضية
WO2020068798A1 (en) 2018-09-24 2020-04-02 Guo Jimin Living mammalian cells modified with functional modular nanoparticles
CN113874525A (zh) * 2018-10-29 2021-12-31 分子听诊器公司 使用无细胞信使rna的骨髓表征
US12208164B2 (en) 2019-02-28 2025-01-28 Unm Rainforest Innovations Modular metal-organic polyhedra superassembly compositions
BR112021025105A2 (pt) * 2019-06-12 2022-03-15 Reven Ip Holdco Llc Métodos e composições para melhorar os resultados de pacientes com câncer
JP2023512214A (ja) 2020-01-28 2023-03-24 リフレクション メディカル， インコーポレイテッド 放射性核種および外部ビーム放射線療法の共同最適化

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US470753A (en) * 1892-03-15 William grunow
US587451A (en) * 1897-08-03 James douglas o neill
US410436A (en) * 1889-09-03 packham
US158393A (en) * 1875-01-05 Improvement in grates
US96393A (en) * 1869-11-02 Improved furniture-caster
US589190A (en) * 1897-08-31 Apparatus for compressing air
US118508A (en) * 1871-08-29 Improvement in flour-bolts
US716818A (en) * 1901-04-13 1902-12-23 James A Ekin Criswell Machine for making matches.
US937333A (en) * 1909-06-26 1909-10-19 William H Shugart Rail-joint.
GB750155A (en) * 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) * 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US3398097A (en) * 1965-07-30 1968-08-20 Progressive Products Co Cleaning composition, and method of cleaning and sequestering metal ions
BE744394A (en) * 1970-01-14 1970-07-14 Elphiac Sa Zone refining process
US3726912A (en) * 1970-07-02 1973-04-10 Dow Chemical Co Substituted alkanolamine chelating agents
US3989730A (en) * 1972-06-15 1976-11-02 Research Corporation Bone-seeking technetium-99m complex
US3852414A (en) * 1972-09-13 1974-12-03 New England Nuclear Corp Bone seeking technetium 99m stannous phosphate complex
PH12898A (en) * 1973-05-23 1979-10-04 Procter & Gamble A composition for the treatment of calcific tumors
US3965254A (en) * 1973-05-23 1976-06-22 The Procter & Gamble Company Compositions for the treatment of calcific tumors
US3931396A (en) * 1973-05-31 1976-01-06 Commissariat A L'energie Atomique Method of preparation of a composition having a base of 99m technetium for diagnosis by scintigraphy
US4058704A (en) * 1974-12-27 1977-11-15 Taeo Kim Coilable and severable heating element
US4017596A (en) * 1975-03-03 1977-04-12 Research Corporation Radiopharmaceutical chelates and method of external imaging
US3974268A (en) * 1975-05-30 1976-08-10 Research Corporation Bone-seeking technetium-99m imidodiphosphonate complex
DE2543349C2 (de) 1975-09-29 1984-05-10 Henkel KGaA, 4000 Düsseldorf Preaparate zur herstellung von99m technetium-radiagnostica
US4075314A (en) * 1976-04-29 1978-02-21 Mallinckrodt, Inc. Stannous pyrophosphate technetium-99m compositions
CA1078731A (en) * 1976-12-16 1980-06-03 Charles E. Frosst And Co. Skeletal imaging kit utilizing triethylene tetramine hexa (methylene phosphonic acid)
US4399817A (en) * 1981-06-30 1983-08-23 The Procter & Gamble Company Boron containing polyphosphonates for the treatment of calcific tumors
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4508625A (en) * 1982-10-18 1985-04-02 Graham Marshall D Magnetic separation using chelated magnetic ions
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
DE3247054C1 (de) * 1982-12-20 1984-05-10 Goetze Ag, 5093 Burscheid Spritzpulver fuer die Herstellung verschleissfester Beschichtungen
SE8301395L (sv) 1983-03-15 1984-09-16 Wallac Oy Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler
US4515767A (en) * 1983-06-20 1985-05-07 The Dow Chemical Company Radioactive metals complexed with phosphonate derivatives of dicyclopentadienebis(methylamine)
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
US4560548A (en) * 1984-04-10 1985-12-24 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US5059412A (en) 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
IL74902A (en) 1984-06-04 1990-12-23 Dow Chemical Co Organic amine phosphonic acid complexes with particle-emitting radionuclides for the treatment of calcific tumors
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5066478A (en) * 1984-06-04 1991-11-19 The Dow Chemical Company Radio labeled organic amine phosphonic acid complexes for the treatment of calcific tumors
US4606907A (en) * 1984-07-02 1986-08-19 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of polyamidoamines
US4897254A (en) * 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US4678687A (en) * 1984-10-31 1987-07-07 Xerox Corporation Thermal transfer printing sheets containing certain coating compositions thereof
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5556982A (en) * 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4752464A (en) * 1985-06-07 1988-06-21 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
GB8518300D0 (en) 1985-07-19 1985-08-29 Amersham Int Plc Contrast agent
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3772785D1 (de) 1986-01-23 1991-10-17 Squibb & Sons Inc 1-substituiertes-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecan und analoga.
DE3625417C2 (de) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
AU608759B2 (en) 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
FR2614020B1 (fr) 1987-04-14 1989-07-28 Guerbet Sa Nouveaux ligands cycliques azotes, complexes metalliques formes par ces ligands, compositions de diagnostic contenant ces complexes et procede de preparation des ligands.
US4853209A (en) * 1987-05-18 1989-08-01 The Dow Chemical Company Bone marrow suppressing agents
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5202109A (en) * 1988-06-10 1993-04-13 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US4976950A (en) 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
US4937333A (en) 1989-08-04 1990-06-26 The Dow Chemical Company Method for purifying aminomethylenephosphonic acids for pharmaceutical use
US4882142A (en) * 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
GB8903023D0 (en) 1989-02-10 1989-03-30 Parker David Chemical compounds
US5714467A (en) * 1989-04-12 1998-02-03 The Rockefeller University Antibacterial and antimalarial hybrid peptides
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5064433A (en) * 1990-03-05 1991-11-12 Helix Medical, Inc. Voice prosthesis insertion assemblies
EP0455380B1 (en) 1990-04-18 1997-01-15 Celltech Therapeutics Limited Tetra-aza macrocycles; processes for their preparation, and their use in magnetic resonance imaging
WO1991016075A1 (en) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Bone marrow treatments
ES2071319T3 (es) * 1990-06-15 1995-06-16 Hoechst Schering Agrevo Gmbh Polipeptido antifungico, procedimiento para su preparacion.
MC2260A1 (fr) * 1990-06-18 1993-04-26 Dow Chemical Co Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
CA2089368C (en) * 1990-08-20 2002-08-06 Hiromitsu Iwata Antibacterial penem esters derivatives
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5503840A (en) 1991-08-09 1996-04-02 E. I. Du Pont De Nemours And Company Antimicrobial compositions, process for preparing the same and use
US5861430A (en) * 1991-12-17 1999-01-19 Jasmine Fockerman Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents
US5919925A (en) * 1992-01-22 1999-07-06 Pfizer Inc. 2-isocephem and oxacephem derivatives and use as antibacterial agents
DE69331319T2 (de) 1992-06-09 2002-08-08 Neorx Corp., Seattle Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
PL173704B1 (pl) * 1992-10-28 1998-04-30 Den Mat Corp Bezalkoholowa, przeciwbakteryjna kompozycja do higieny jamy ustnej
US5714604A (en) 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
AP9500775A0 (en) * 1993-08-24 1996-01-31 Janssen Pharmaceutica Nv Antibacterial and antifouling oxathiazines and their oxides
US5587451A (en) 1993-11-26 1996-12-24 The Dow Chemical Company Process for preparing polyazamacrocycles
FR2719481B1 (fr) * 1994-05-05 1996-05-31 Oreal Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux.
EP0787720B1 (en) * 1994-10-20 2003-07-16 Wakunaga Seiyaku Kabushiki Kaisha Pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient
SK88496A3 (en) * 1994-11-08 1997-04-09 Glaxo Wellcome Sa Cyclic derivatives, manufacturing process thereof, pharmaceutical compositions containing them and their use antifungal sordaridin derivatives
JPH09512831A (ja) * 1994-11-17 1997-12-22 エフ・ホフマン−ラ ロシュ アーゲー ジベンズイミダゾール誘導体
KR980700077A (ko) * 1994-11-29 1998-03-30 나까토미 히로타카 2-아미노티아졸유도체 및 그 염류로 이루어진 항균제 또는 살균제(Antibacterial Prepartion or Bactericide comprising 2-Aminothiazole Derivative or Salt Thereof
US5773421A (en) * 1995-01-10 1998-06-30 Abbott Laboratories Antifungal fusacandins
CA2211138A1 (en) * 1995-01-26 1996-08-01 Merck & Co., Inc. Novel antifungal cyclohexapeptides
US5849956A (en) * 1995-02-08 1998-12-15 Plant Biological Defense System Laboratories Antifungal terpene compounds and process for producing the same
JP3081773B2 (ja) * 1995-03-31 2000-08-28 株式会社資生堂 Ｎ−アシルピペラジン誘導体及び抗菌剤、抗潰瘍剤
US5786325A (en) * 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
JPH10507205A (ja) * 1995-08-02 1998-07-14 ホータ．ウリアッヒ イ シイア．エセ．アー． 抗真菌活性を有する新規カルボンアミド
DK0783501T3 (da) * 1995-08-02 2001-01-29 Uriach & Cia Sa J Pyrimidonderivater med anti-fungal aktivitet
US5681430A (en) * 1995-08-23 1997-10-28 Thermo Fibertek Inc. Activity induction in papermaking
US5872249A (en) * 1995-09-01 1999-02-16 Korea Institute Of Science And Technology 3-ammoniopropenyl cephalosporin compounds as antibacterial agents and process for preparing the same
WO1997009878A1 (en) * 1995-09-15 1997-03-20 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
JPH11511467A (ja) * 1995-09-15 1999-10-05 ファルマシア・アンド・アップジョン・カンパニー ５−アミドメチルα，β−飽和および不飽和３−アリールブチロラクトン抗菌剤
US5837726A (en) * 1995-11-01 1998-11-17 Millennium Pharmaceuticals, Inc. Antifungal agents derived from aspergillus fumigatus
EP0781566B1 (en) * 1995-12-26 2004-07-28 Toyo Boseki Kabushiki Kaisha Organic solvent-soluble mucopolysaccharide, antibacterial antithrombogenic composition and medical material
US5756472A (en) * 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP4058129B2 (ja) * 1996-03-18 2008-03-05 株式会社資生堂 ピリジン誘導体及び抗潰瘍剤、抗菌剤
US5770617A (en) * 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
US5773696A (en) * 1996-03-29 1998-06-30 Monsanto Company Antifungal polypeptide and methods for controlling plant pathogenic fungi
JP3693449B2 (ja) * 1996-04-05 2005-09-07 三菱製紙株式会社 抗菌防黴剤およびそれを含有する繊維状物質
JP4150435B2 (ja) * 1996-04-18 2008-09-17 株式会社資生堂 アルキレンジアミン誘導体及び抗潰瘍剤、抗菌剤
US5756725A (en) * 1996-04-24 1998-05-26 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
US5917084A (en) * 1996-07-03 1999-06-29 Millennium Pharmaceuticals, Inc. Antifungal agents
GB2315489A (en) * 1996-07-17 1998-02-04 Merck & Co Inc Antifungal agent
US5837253A (en) * 1996-07-26 1998-11-17 Agrogene Ltd. Preparation and use of Inula extracts as a fungicide for the control of plant diseases
US5908862A (en) * 1996-07-31 1999-06-01 Abbot Laboratories Water-miscible esters of mono--and diglycerides having antibacterial activity and their use in inhibiting infection
UA51730C2 (uk) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
US5830855A (en) * 1996-09-12 1998-11-03 Utah State University Lipodepsipeptides as antifungal and fungicidal agents
US5876738A (en) * 1996-10-29 1999-03-02 Toagosei Co., Ltd. Antifungal phyllosilicate
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
JP4090087B2 (ja) * 1997-04-04 2008-05-28 株式会社資生堂 ベンズアミド誘導体及び抗潰瘍剤、抗菌剤
US5863773A (en) * 1997-09-30 1999-01-26 Abbott Laboratories Antifungal corynecandin
DE19911329A1 (de) 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
CA2371728C (en) 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
WO2001091806A2 (en) 2000-05-31 2001-12-06 Steven Mccullough Measurement of the therapeutic dose for bone marrow ablation therapy
WO2002062398A2 (en) 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
WO2003051403A1 (en) * 2001-12-13 2003-06-26 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals

Also Published As

Publication number Publication date
US7097823B2 (en) 2006-08-29
WO2000076556A3 (en) 2001-10-11
US7378077B2 (en) 2008-05-27
US6767531B2 (en) 2004-07-27
CA2371728C (en) 2009-06-02
US20070053833A1 (en) 2007-03-08
US20050129667A1 (en) 2005-06-16
CA2371728A1 (en) 2000-12-21
US20050063905A1 (en) 2005-03-24
JP2003501488A (ja) 2003-01-14
WO2000076556A9 (en) 2001-11-08
US7408046B2 (en) 2008-08-05
WO2000076556A2 (en) 2000-12-21
US7070759B2 (en) 2006-07-04
US20050238578A1 (en) 2005-10-27
US7696331B2 (en) 2010-04-13
US20090136419A1 (en) 2009-05-28
US20020176818A1 (en) 2002-11-28
EP1191948A2 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
AU5871000A (en) High dose radionuclide complexes for bone marrow suppression
AU5308700A (en) Radiation shield
HUP0200185A3 (en) Improved powdery pharmaceutical compositions for inhalation
AU2452801A (en) Packaging system for medical components
AU5287000A (en) Parallel x-ray nanotomography
HUP0200818A2 (en) Powder inhaler for combined medicament
IL133031A0 (en) Powder inhaler
HUP0104255A3 (en) An pharmaceutical composition suitable for inhalation
AU5271300A (en) Radiopaque compositions
HUP0200855A2 (en) Powder inhaler for combined medicament
IL145290A0 (en) Pharmaceutical compositions comprising complexes
HUP0104657A3 (en) Imidazole compounds and pharmaceutical compositions containing them
AU4392199A (en) Medicinal compositions for treating evacuatory insufficiency
AU6676900A (en) Containment chamber for dental abrasion
HUP0102894A3 (en) A substituted triazolo-pyridazine derivative, pharmaceutical compositions containing them
IL142534A0 (en) Pharmaceutical compositions containing an antigen-adjuvent
GB9800750D0 (en) Pharmaceutical compound
GB9916434D0 (en) Pharmaceutical compounds
AU2196301A (en) Breast shield
AU3410099A (en) Pharmaceutical compositions containing melatonin inclusion complexes
GB9914255D0 (en) Pharmaceutical compounds
GB0014860D0 (en) Shield
GB9903784D0 (en) Pharmaceutical compounds
AU5706500A (en) Medicinal compositions for treating colorectal cancer
AU4783499A (en) Method for preparing virus-safe pharmaceutical compositions

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase